Article

Is ASDAS better than BASDAI as a measure of disease activity in axial psoriatic arthritis?

Centre for Prognosis Studies in the Rheumatic Diseases, University of Toronto Psoriatic Arthritis Clinic, Toronto Western Hospital, Toronto, Ontario, Canada.
Annals of the rheumatic diseases (Impact Factor: 10.38). 12/2010; 69(12):2160-4. DOI: 10.1136/ard.2010.129726
Source: PubMed

ABSTRACT To assess the discriminative ability and correlation of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and Bath Ankylosing Spondylitis Activity Disease Activity Index (BASDAI) with disease activity in axial psoriatic arthritis (AxPsA).
Patients with AxPsA were selected from a large prospective cohort study of psoriatic arthritis. Patient and physician global scores were used as constructs of disease activity. Patients were categorised into high and low disease activity states based on patient and physician global assessment scores and physician's decision to change treatment. Statistical analysis included descriptive statistics, linear and logistic regression.
201 patients with AxPsA were included in the study. ASDAS and BASDAI showed good correlation with disease activity as reflected by the patient global score (correlation coefficients (r) for BASDAI 0.84, ASDAS-B 0.77, ASDAS-C 0.81, p < 0.001) and the physician global score (r = 0.53 for BASDAI, r = 0.50 for ASDAS-B, r = 0.55 for ASDAS-C, p < 0.001). Both scores showed good discriminative ability between high and low disease activity states. However, there were no significant differences between areas under the curve for the models that compared ASDAS with BASDAI for each definition of disease activity state.
In patients with AxPsA, ASDAS and BASDAI scores show similar good to moderate discriminative ability and correlation with different constructs of disease activity. ASDAS was not superior to BASDAI in its ability to discriminate between high and low disease activity states in AxPsA.

Download full-text

Full-text

Available from: Lihi Eder, Mar 23, 2014
1 Follower
 · 
307 Views
  • Source
    • "Clinical and ultrasonographic (US) evaluation of the lateral surface of the head of the 5th metatarsal bone were performed in all PsA patients and controls focusing on the detection of inconstant bursitis on this site. Disease activity was assessed in all SpA and PsA patients in accordance with the currently available indices, that is, ASDAS (Ankylosing Spondylitis Disease Activity Score) for AS and uSpA [7] [8]; DAREA (Disease Activity Index for Reactive Arthritis) for ReA [9]; DAPSA (Disease Activity Index for Psoriatic Arthritis) and ASDAS for PsA [10] [11]. The last two scores (DAPSA and ASDAS) were also used for the assessment of IBD-SpA disease activity. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective. To evaluate the involvement of the bursa located next to the head of the 5th metatarsal bone in patients with psoriatic arthritis (PsA) in comparison with the other seronegative spondyloarthritis (SpA). Methods. All patients with PsA seen during a period of 24 months were enrolled. The control group included healthy subjects and patients with the other SpA. All subjects underwent clinical and ultrasound (US) examination of the lateral surface of the 5th metatarsal. Results. 150 PsA patients (88 M; 62 F), 172 SpA (107 M; 65 F), and 95 healthy controls (58 M; 37 F) were evaluated. Based on clinical and US evaluation, bursitis was diagnosed in 17/150 (11.3%) PsA patients but in none of the SpA (P < 0.0001) and healthy (P = 0.0002) controls. In detecting bursitis, US was more sensitive than clinical examination, although the difference did not reach statistical significance (P = 0.09). Conclusion. The bursa of the 5th metatarsophalangeal joint appears to be involved in PsA more frequently than by chance. If confirmed by other studies, this finding could be considered as a distinctive clinical sign of PsA, useful for differential diagnosis with the other SpA. In asymptomatic patients, US proved to be more sensitive in the detection of bursitis.
    BioMed Research International 07/2014; 2014:174841. DOI:10.1155/2014/174841 · 2.71 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Psoriatic arthritis can manifest in various ways, which complicates its assessment. The availability of novel effective therapies required the development of new outcome measurement tools for assessment of the different aspects of the disease in clinical trials and observational studies. Significant progress has been made in our ability to quantify the activity of the different presentations of the disease. A core set of domains was recommended by Outcome Measures in Rheumatology (OMERACT) and Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) for use in clinical trials and observational studies in patients with psoriatic disease. The core set includes the assessment of skin, nails, joints, enthesitis, dactylitis and spinal disease in addition to patient reported outcomes and quality of life. This manuscript reviews the various measurement tools that are commonly used for the assessment of these domains in patients with psoriatic disease.
    09/2013; 2(3). DOI:10.1007/s13671-013-0050-1
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Due to the amount and quality variability regarding the use of biologic therapy (BT) in psoriatic arthritis (PsA) patients, the Spanish Society of Rheumatology (SER) has promoted the generation of recommendations based on the best evidence available. These recommendations should serve as reference to rheumatologists and those involved in the treatment of patients with PsA, who are using, or about to use BT. Recommendations were developed following a nominal group methodology and based on systematic reviews. The level of evidence and degree of recommendation was classified according to the model proposed by the Center for Evidence Based Medicine at Oxford. The level of agreement was established through Delphi technique. We have produced recommendations for the use of TB currently available for PsA in our country. These recommendations include disease assessment, treatment objectives, therapeutic scheme and switching. We present an update on the SER recommendations for the use of BT in patients with PsA.
    05/2011; 7(3):179-88. DOI:10.1016/S2173-5743(11)70038-7
Show more

Similar Publications